Craft

Black Diamond Therapeutics

Stock Price

$4.9

2024-02-26

Market Capitalization

$252 M

2024-02-26

Black Diamond Therapeutics Summary

Company Summary

Overview
Black Diamond Therapeutics is a biotechnology company. It is focused on the development of selective medicines for patients with genetically-defined cancers driven by oncogenes activated by allosteric mutations.
Type
Public
Status
Active
Founded
2017
HQ
Cambridge, MA, US | view all locations
Website
https://www.blackdiamondtherapeutics.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • David M. Epstein

    David M. Epstein, Co-Founder, President & Chief Executive Officer

  • Ali Behbahani

    Ali Behbahani, Director

    • Elizabeth Buck

      Elizabeth Buck, Co-Founder, Chief Scientific Officer

    • Wendy Dixon

      Wendy Dixon, Director

      Operating MetricsView all

      Patent Applications

      7

      Jan, 2020

      LocationsView all

      4 locations detected

      • Cambridge, MA HQ

        United States

        1 Main St

      • New York, NY

        United States

        180 Varick St 6th floor

      • Stony Brook, NY

        United States

        25 Health Sciences Drive

      • Toronto, ON

        Canada

        MaRS Centre for Impact Investing, West Tower, 661 University Ave Suite 1300

      Black Diamond Therapeutics Financials

      Summary Financials

      Net income (Q3, 2023)
      ($23.0M)
      Cash (Q3, 2023)
      $58.0M
      EBIT (Q3, 2023)
      ($24.0M)
      Enterprise value
      $220.0M

      Footer menu